V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330007378 | 330004182 | 1.73 | 61.6 | Neo-adjuvant (N) | null | 2015-02-21 | OST Euramos 1 Closed Trial - AP | N | N | 330009285 | MAP |
| 330007380 | 330004187 | 1.6 | 61.3 | Neo-adjuvant (N) | 2018-06-15 | 2018-06-15 | Etoposide + Ifosfamide (3 days) | 2 | N | 330009299 | ETOPOSIDE + IFOSFAMIDE |
| 330007381 | 330004188 | 1.63 | 85 | Palliative (P) | 2018-01-07 | 2018-01-07 | Docetaxel + Gemcitabine (prior RT) | N | N | 330009304 | DOCETAXEL + GEMCITABINE |
| 330007382 | 330004189 | null | 52.65 | Palliative (P) | 2017-05-18 | 2017-05-18 | Docetaxel+Gemcitabine (no prior RT) | null | null | 330009306 | DOCETAXEL + GEMCITABINE |
| 330007383 | 330008290 | null | 61 | null | 2013-12-03 | 2013-12-03 | OST Euramos 1 Closed Trial - M | N | N | 330009311 | METHOTREXATE HIGH DOSE |
| 330007384 | 330004191 | 1.8 | 74.9 | Curative (C) | 2016-02-28 | 2016-03-14 | CISPLATIN + FLUOROURACIL | N | N | 330009329 | CISPLATIN + FLUOROURACIL |
| 330007385 | 330008291 | 1.7 | 54 | Curative (C) | 2014-09-28 | 2014-10-26 | Rituximab (Maintenance) | N | N | 330009333 | RITUXIMAB |
| 330007386 | 330008291 | 1.81 | 58.7 | Curative (C) | 2016-05-13 | 2016-05-31 | PAM x 2 post-surgery (cycles 3&4) | N | N | 330009333 | MAP |
| 330007387 | 330008292 | 1.64 | 58.2 | Adjuvant (A) | null | 2014-06-29 | CISPLATIN + FLUOROURACIL | N | N | 330009344 | CISPLATIN + FLUOROURACIL |
| 330007388 | 330010494 | 1.68 | 69.9 | Curative (C) | null | 2014-07-02 | OST Euramos 1 Closed Trial - AP | 02 | N | 330009369 | MAP |
| 330007389 | 330004193 | 1.7 | 100.8 | Neo-adjuvant (N) | 2016-12-14 | 2017-01-11 | Docetaxel+Gemcitabine (no prior RT) | N | N | 330009369 | DOCETAXEL + GEMCITABINE |
| 330007390 | 330004193 | null | null | Palliative (P) | 2016-08-21 | 2016-09-30 | Rituximab | N | N | 330009369 | RITUXIMAB |
| 330007391 | 330011721 | 1.69 | 136.5 | Curative (C) | 2013-12-14 | 2013-12-28 | ETOPOSIDE + IFOSFAMIDE | 02 | N | 330009388 | ETOPOSIDE + IFOSFAMIDE |
| 330007392 | 330004194 | 1.78 | 82 | null | 2014-01-28 | 2014-02-19 | OST Euramos 1 Closed Trial - M | 02 | N | 330009403 | METHOTREXATE HIGH DOSE |
| 330007393 | 330008294 | null | 89.6 | Palliative (P) | 2016-04-28 | 2016-04-28 | Rituximab | 1 | N | 330009403 | RITUXIMAB |
| 330007394 | 330004195 | 1.64 | 76 | Curative (C) | null | 2014-12-01 | Methotrexate High Dose (3g/m2) | N | N | 330009422 | METHOTREXATE HIGH DOSE |
| 330007395 | 330004195 | 1.65 | null | Curative (C) | 2015-12-14 | 2015-12-14 | Cetuximab 14 day | N | N | 330009422 | CETUXIMAB |
| 330007396 | 330004197 | 0 | null | Palliative (P) | 2013-04-28 | 2013-06-02 | Carboplatin AUC 2 - 5 | N | null | 330009441 | CARBOPLATIN |
| 330007397 | 330004198 | 0 | null | Palliative (P) | null | 2015-06-17 | Etoposide + Ifosfamide (3 days) | null | null | 330009445 | ETOPOSIDE + IFOSFAMIDE |
| 330007398 | 330004199 | 1.83 | null | Palliative (P) | 2017-06-16 | 2017-06-16 | Rituximab | N | N | 330009446 | RITUXIMAB |
| 330007399 | 330004201 | 1.83 | 82.2 | Palliative (P) | 2016-11-16 | 2016-11-16 | PAM x 2 post-surgery (cycles 3&4) | N | N | 330009450 | MAP |
| 330007400 | 330004202 | 1.65 | 69.2 | Curative (C) | 2019-07-30 | 2019-08-12 | Docetaxel + Gemcitabine (prior RT) | N | N | 330009450 | DOCETAXEL + GEMCITABINE |
| 330007401 | 330004202 | 1.69 | null | null | 2017-05-11 | 2017-06-05 | Rituximab | Y | N | 330009450 | RITUXIMAB |
| 330007402 | 330004203 | 1.54 | null | Curative (C) | 2015-07-13 | 2015-08-06 | Docetaxel + Gemcitabine (prior RT) | 02 | N | 330009693 | DOCETAXEL + GEMCITABINE |
| 330007403 | 330004205 | 1.81 | 73.6 | Curative (C) | 2017-10-12 | 2017-10-13 | PAM x 2 post-surgery (cycles 3&4) | 02 | N | 330009744 | MAP |
| 330007404 | 330010500 | 1.59 | 65.8 | Curative (C) | null | 2017-05-18 | Rituximab | N | N | 330009744 | RITUXIMAB |
| 330007405 | 330004214 | 1.62 | 42.7 | Palliative (P) | 2015-05-24 | 2015-07-03 | CETUXIMAB | N | N | 330009847 | CETUXIMAB |
| 330007406 | 330008305 | 1.64 | 82 | Curative (C) | 2016-10-02 | 2016-10-07 | Rituximab | N | N | 330009871 | RITUXIMAB |
| 330007407 | 330004218 | null | 60.2 | Curative (C) | null | 2016-10-31 | Docetaxel+Gemcitabine (no prior RT) | N | N | 330009871 | DOCETAXEL + GEMCITABINE |
| 330007408 | 330004218 | 0 | 74.65 | Neo-adjuvant (N) | 2013-06-18 | 2013-06-25 | OST Euramos 1 Closed Trial - M | N | N | 330009871 | METHOTREXATE HIGH DOSE |
| 330007409 | 330004219 | 1.75 | 69.3 | Palliative (P) | 2016-07-13 | 2016-07-13 | Rituximab (Maintenance) | 02 | N | 330010223 | RITUXIMAB |
| 330007410 | 330004221 | 1.6 | 58.4 | Neo-adjuvant (N) | 2013-11-12 | 2013-12-09 | Cisplatin +Fluorouracil (3 wk) | 02 | null | 330010343 | CISPLATIN + FLUOROURACIL |
| 330007411 | 330004222 | 1.65 | 95 | null | 2014-06-03 | 2014-08-11 | Rituximab (SUBCUTANEOUS Maintenance) | 2 | N | 330010440 | RITUXIMAB |
| 330007412 | 330008308 | 1.87 | 62.8 | Palliative (P) | 2016-07-18 | 2016-07-18 | Docetaxel + Gemcitabine (prior RT) | 02 | Y | 330010452 | DOCETAXEL + GEMCITABINE |
| 330007413 | 330004223 | 1.62 | 58 | Palliative (P) | null | 2015-04-14 | Cetuximab 7 day (>Cycle 2) | 2 | N | 330010452 | CETUXIMAB |
| 330007414 | 330004223 | null | 70.5 | Adjuvant (A) | null | 2013-11-25 | OST Euramos 1 Closed Trial - M | Y | N | 330010452 | METHOTREXATE HIGH DOSE |
| 330007415 | 330008310 | 1.69 | null | Curative (C) | null | 2016-06-06 | Carboplatin AUC 2 - 5 | N | N | 330010479 | CARBOPLATIN |
| 330007416 | 330004226 | 1.78 | 39.2 | Palliative (P) | null | 2018-04-28 | DOCETAXEL + GEMCITABINE | N | N | 330010479 | DOCETAXEL + GEMCITABINE |
| 330007417 | 330008313 | 1.74 | 58.2 | Not known (9) | null | 2015-12-29 | MAP | N | N | 330010510 | MAP |
| 330007418 | 330008313 | 1.86 | 58.5 | null | 2018-06-08 | 2018-07-12 | Rituximab (INTRAVENOUS Maintenance) | N | N | 330010510 | RITUXIMAB |
| 330007419 | 330008313 | 1.71 | 62 | Palliative (P) | 2013-10-12 | 2013-10-12 | Docetaxel + Gemcitabine (prior RT) | Y | N | 330010510 | DOCETAXEL + GEMCITABINE |
| 330007420 | 330004229 | 1.71 | 151 | Neo-adjuvant (N) | 2013-04-18 | 2013-04-23 | Docetaxel+Gemcitabine (no prior RT) | N | N | 330010563 | DOCETAXEL + GEMCITABINE |
| 330007421 | 330010509 | 0 | 77.5 | Curative (C) | 2013-10-11 | 2013-10-11 | Rituximab | 02 | N | 330010567 | RITUXIMAB |
| 330007424 | 330004235 | 1.67 | 73 | Disease modification (D) | 2015-08-07 | 2015-08-18 | Rituximab | N | null | 330010602 | RITUXIMAB |
| 330007425 | 330008318 | 0 | 82 | Adjuvant (A) | 2014-04-02 | 2014-05-11 | OST Euramos 1 Closed Trial - AP | N | N | 330010610 | MAP |
| 330007426 | 330004237 | 1.68 | 55.2 | Curative (C) | 2017-02-27 | 2017-03-27 | DOCETAXEL + GEMCITABINE | N | N | 330010616 | DOCETAXEL + GEMCITABINE |
| 330007427 | 330004238 | 1.77 | 103 | Curative (C) | 2012-11-27 | 2013-01-09 | Cisplatin +Fluorouracil (3 wk) | 2 | N | 330010618 | CISPLATIN + FLUOROURACIL |
| 330007428 | 330004238 | 1.81 | 57.2 | Palliative (P) | 2014-03-13 | 2014-04-03 | Cisplatin +Fluorouracil (3 wk) | 2 | N | 330010618 | CISPLATIN + FLUOROURACIL |
| 330007429 | 330004239 | 1.6 | 54 | Adjuvant (A) | 2014-06-20 | 2014-07-18 | PAM x 2 post-surgery (cycles 3&4) | N | N | 330010656 | MAP |
| 330007430 | 330004240 | 1.64 | null | Curative (C) | 2014-10-19 | 2014-11-04 | OST Euramos 1 Closed Trial - M | N | N | 330010659 | METHOTREXATE HIGH DOSE |